The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial.
Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jörres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK. · 2017
Read The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. by Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jörres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5662220.txt.
Introduction
Schädler and co-authors report a randomized trial in PLoS ONE. It tests a blood filtering device in septic patients. The CytoSorb device adsorbs cytokines from blood outside the body. Patients had severe sepsis or septic shock with lung failure. All were on mechanical ventilation. Treatment ran six hours daily for up to seven days. The main outcome was change in blood IL-6 levels.
Of 100 randomized patients, 97 were analyzed. The device removed IL-6 at each blood pass. Removal averaged between five and eighteen percent per pass. Yet plasma IL-6 levels did not differ between groups. Raw mortality looked higher in the treated group. After adjustment for baseline gaps, that link vanished.
Catalog record
| CREATOR | Schädler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jörres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial By Dirk Schädler, Christine Pausch, Daniel Heise, Andreas Meier-Hellmann, Jörg Brederlau, Norbert Weiler, Gernot Marx, Christian Putensen, Claudia Spies, Achim Jörres, Michael Quintel, Christoph Engel Published in: PLoS ONE DOI: 10.1371/journal.pone.0187015 ABSTRACT Objective We report on the effect of hemoadsorption therapy to reduce cytokines in septic patients with respiratory failure. Methods This was a randomized, controlled, open-label, multicenter trial. Mechanically ventilated patients with severe sepsis or septic shock and acute lung injury or acute respiratory distress syndrome were eligible for study inclusion. Patients were randomly assigned to either therapy with CytoSorb hemoperfusion for 6 hours per day for up to 7 consecutive days (treatment), or no hemoperfusion (control). Primary outcome was change in normalized IL-6-serum concentrations during study day 1 and 7. Results 97 of the 100 randomized patients were analyzed. We were not able to detect differences in systemic plasma IL-6 levels between the two groups (n = 75; p = 0.15). Significant IL-6 elimination, averaging between 5 and 18% per blood pass throughout the entire treatment period was recorded. In the unadjusted analysis, 60-day-mortality was significantly higher in the treatment group (44.7%) compared to the control group (26.0%; p = 0.039). The proportion of patients receiving renal replacement therapy at the time of enrollment was higher in the treatment group (31.9%) when compared to the control group (16.3%). After adjustment for patient morbidity and baseline imbalances, no association of hemoperfusion with mortality was found (p = 0.19). Conclusions In this patient population with predominantly septic shock and multiple organ failure, hemoadsorption removed IL-6 but this did not lead to lower plasma IL-6-levels. We did not detect statistically significant differences in the secondary outcomes multiple organ dysfunction score, ventilation time and time course of oxygenation. INTRODUCTION At the early onset of sepsis [1] an overshoot of multiple pro-inflammatory mediators is often observed, caused by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [2]. It is known that mortality is highest when both pro- and anti-inflammatory cytokine levels are highest [3]. It has been suggested that blocking this overproduction would stop sepsis and improve patient outcomes. Therapeutic monoclonal antibodies targeting specific cytokines such as tumor necrosis factor-α (anti-TNF-α) have demonstrated mortality benefit in animal sepsis models and small scale human sepsis studies [4,5] but have not succeeded in large scale pivotal trials in septic patients. There are no currently approved specific therapies to treat sepsis, following the withdrawal of recombinant activated protein C (Xigris; Eli Lilly, USA) from the market in 2011 following the results of the PROWESS-SHOCK trial [6,7]. Another approach to decrease cytokine overproduction is extracorporeal blood purification. De Vriese et al. observed a significant short-term decrease of pro- and anti-inflammatory cytokines one hour after the start of continuous venovenous hemofiltration in patients with septic shock and acute kidney injury [4]. However, moderate sized trials of standard [5] or high-volume hemofiltration [6] did not show an improvement of survival and did not influence plasma cytokine levels measured in a small subgroup [5]. In a recent meta-analysis of the various forms of blood purification, only plasma exchange, and hemoadsorption appeared to be potentially effective for treatment of sepsis [7]. Hemoperfusion using polymyxin b is currently used in the treatment of sepsis in Japan [8–12]. The EUPHAS study, a randomized controlled multi-center trial investigating the effect of polymyxin b hemoperfusion in patients with abdominal septic shock showed promising results as vasopressor requirements in the hemoperfusion group was significantly lower, and the P-F-ratio (partial pressure of oxygen divided by the inspired fraction of oxygen) was significantly higher compared to controls. In a post-hoc analysis, hemoperfusion was associated with improved survival [13]. However, in a large randomized controlled multi-center trial in France, Payen et al. did not detect a significant effect of hemoperfusion on mortality or improvement of organ dysfunction [14]. CytoSorb (Cytosorbents, Corporation, New Jersey, USA) is a hemoadsorption device containing hemocompatible, porous polymeric beads capable of removing cytokines and other mid-molecular weight toxins from blood by size exclusion and surface adsorption. The polymer is both highly adsorptive and biocompatible and has been approved in the European Union. Multiple pre-clinical studies using animal models of sepsis have demonstrated reductions in various circulating cytokines and chemokines, reduced organ injury, and improved survival [15–18]. Kellum et al. detected reduction rates in circulating IL-6 in the range of 56% to 78% in an experimental endotoxemia setting [15]. A feasibility study in brain-dead humans confirmed reductions in cytokines without any adverse effects [19]. In that study, the authors reported IL-6 extraction rates ranging from 27.5% to 30.2%. Thus, in this “first-in-septic patients” phase 2 randomized, controlled clinical trial, we sought to investigate the efficacy of cytokine reduction using the change in plasma interleukin (IL)-6 concentrations over time as a primary outcome. Although the trial was neither designed nor powered to evaluate outcome, we also evaluated organ function parameters as well as all-cause mortality. METHODS This open label, randomized, controlled multi-center trial was conducted in 10 German study sites during April 2008 (first patient in) and June 2011 (last patient out). The study was approved by the ethics committee of Göttingen University and registered at clinicaltrials.gov (NCT00559130). Mechanically ventilated patients with severe sepsis or septic shock according to the American College of Chest Physicians and Society of Critical Care Medicine criteria [20] in the setting of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) according to the American-European consensus definition [21] established within the last 72 hours were eligible for study inclusion (please see S3 File for all inclusion and exclusion criteria). Before study inclusion, written informed consent was obtained from all patients. If a patient was not able to give consent the legal representative was asked to consent. In the latter case patients were asked to give study consent after being capable to understand the study’s nature and importance. Patients were randomly assigned either to be treated with standard of care therapy and CytoSorb hemoperfusion for 6 hours per day, up to seven consecutive days (treatment group) or to standard of care therapy alone (control group). In the treatment group, the CytoSorb cartridge was either used alone in hemoperfusion mode or, if renal replacement therapy was clinically indicated, inserted proximally into a conventional continuous veno-venous hemofiltration (CVVH) or continuous veno-venous hemodiafiltration (CVVHDF) circuit. Target blood flow rates were 200–250 mL/min, where blood flow enters the bottom of a vertically-oriented cartridge, and exits through the top. Anti-coagulation using either regional citrate anticoagulation per hospital protocol (target postfilter ionized calcium < 0.4 mmol/l), or systemic heparin anti-coagulation with a target partial thromboplastin time (PTT) of 60–80, or an activated clotting time (ACT) of 180–210, with confirmation of adequate anti-coagulation before initiation of treatment, was recommended. Administration of antibiotics was recommended after CytoSorb treatment where possible. Hemoperfusion was stopped earlier if patients were successfully weaned from mechanical ventilation. Randomization was performed in a 1:1 fashion with a block length of 4, using sealed envelopes prepared by the clinical trial contract research organization, MedPass International (Paris, France). Patients were enrolled and randomized by the local study site investigators. Because of observed and suspected irregularities with regard to